pp-129 Solution for injection
Dossier type
CTD
Dossier status
Under development
Country of origin
China
GMP approvals
China
Comments
Indication: Prevention of RSV lower respiratory tract disease in adults ≥60 years
Clinical stage: Phase 2 — ongoing
Modality: Biologic (recombinant trimeric RSV-F prefusion protein vaccine; AS03-adjuvanted)
Mechanism / Target: Prefusion RSV-F stabilised trimer elicits neutralising antibodies targeting prefusion-specific epitopes (site Ø); broader and stronger immune response than postfusion antigens
Route / form: Intramuscular injection
Differentiation: Proprietary Trimer-Tag technology provides structural stability; AS03 adjuvant enhances immunogenicity in elderly; low-cost manufacturing potential in China
Manufacturer #39165
Clinical-stage vaccine company specialising in recombinant protein-based vaccines. Uses proprietary Trimer-Tag technology platform to stabilise viral fusion proteins. Developing RSV and other respiratory vaccines for global markets.
None